Developing targeted peptides to fight infections and cancer
Dual protease activated peptides for specific targeting
This study is working on new treatments that use special proteins to find and destroy bad cells like bacteria and cancer, while keeping healthy cells safe, so patients can have better and safer options for their care.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10888899 on NIH RePORTER |
What this research studies
This research focuses on creating specialized peptides that can selectively target and kill harmful cells, such as bacteria and cancer cells, while minimizing damage to healthy cells. The approach involves designing prodrugs that are activated by specific enzymes, allowing for precise control over their activity. By modifying the structure of these peptides, the researchers aim to enhance their effectiveness and reduce side effects. Patients may benefit from new treatments that are more effective and safer than current options.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with bacterial infections or specific types of cancer that may benefit from targeted peptide therapies.
Not a fit: Patients with conditions unrelated to bacterial infections or cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for infections and certain cancers.
How similar studies have performed: Other research has shown promise in using protease-activated peptides for targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Tackie-Yarboi, Ethel Naa Odey — University of California, San Francisco
- Study coordinator: Tackie-Yarboi, Ethel Naa Odey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.